Figure 6.

AZD1775 monotherapy suppressed growth of LTED cells. (A, B) Parental cells (MCF7 and T47D) and LTED derivatives (MCF7-LTED and T47D-LTED) were treated with indicated concentration of AZD1775. (C–F) MCF7 and T47D cells and their LTED cells were treated with E2 deprivation (E2 dep), 500nM ribociclib (Ribo), 500nM AZD1775, combination of E2 dep and ribo or the triple combination of E2 dep, ribo and AZD1775 for 6 days. Inhibition of proliferation was measured by crystal violet assays. Data represents the average value ± SE of six replicates of relative number (normalized to vehicle alone). *p < 0.05, ***p < 0.001 and ****p < 0.0001 (ANOVA) for cell number for indicated treatment conditions compared to conditions designated by lines. (G, H) The Bliss and HSA scores using the SynergyFinder R package was used. A score >10 indicates a synergistic interaction, 10 to -10 indicates additivity and <-10 indicates antagonistic interaction between combination of E2 dep+ribo and AZD1775. All experiments were repeated at least three times.